超高和低磁性血症作为埃及败血症儿科患者结果的初始预测因素
1Department of Pediatrics, Faculty of Medicine, Cairo University, Cairo, Egypt.
Acute and critical care
|February 20, 2025
概括
严重疾病的败血症儿童的血清水平可能是一个被忽视的电解质异常. 虽然不是唯一的预测因素,但超血症会对结果产生负面影响,因此在注射时需要谨慎.
科学领域:
- 儿科重症监护医药 儿科重症监护医药
- 临床化学 临床化学
- 败血症的研究研究.
背景情况:
- 严重病的败血症儿童经常经历电解质失衡,包括干扰.
- 这些异常可能会被忽视,可能会影响患者的治疗结果.
- 这项研究研究了初始血清水平与儿科败血症的结果之间的关系.
研究的目的:
- 确定儿科重症监护室 (PICU) 入院的血清含量与重症败血症患者的结果之间的相关性.
- 为了确定儿科败血症死亡率的预测因素.
主要方法:
- 展望性研究涉及76名患有败血症的儿童,从2023年5月至11月.
- 进行了临床和实验室评估,包括初始水平.
- 用多变量逻辑回归和曲线下面积 (AUC) 分析来确定死亡率预测因素.
主要成果:
- 摄入水平的中位数为2.0 mg/dl;在未幸存者中,水平略高.
- 超高血症与患者的负面结果和较低的C-反应蛋白水平有关.
- 儿科序列器官衰竭评估得分 (截止值5.5) 预测了死亡率 (AUC=0.717).
结论:
- 仅仅血清水平不足以作为死亡率的初始预测指标.
- 超血症会对严重患病的败血症儿童产生负面影响.
- 医疗保健专业人员在给这些患者注射时应谨慎行事.
相关概念视频
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
967
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
967
Pharmacokinetics in Pediatric Patients: Drug Distribution
554
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
554
Pharmacokinetics in Pediatric Patients: Drug Metabolism
410
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
410
Acute Pyelonephritis II: Diagnostic Studies and Management
842
Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...
842
Acute Kidney Injury III: Clinical Manifestations
1.8K
Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...
1.8K
Acute Kidney Injury IV: Diagnostic Studies and Prevention
559
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
559


